恶性淋巴瘤的多模态显像研究进展
The research progress of multimodal imaging in malignant lymphoma
医学影像学技术在肿瘤的临床分期、再分期、疗效评价甚至预后判断中发挥着重要作用,多模态影像技术(如PET/CT和PET/MR)近年来发展的非常迅速.18F-FDG PET/CT已广泛用于亲和18F-FDG的恶性淋巴瘤的初始分期以及疗效评估,治疗期间使用18F-FDG PET/CT评估治疗反应的价值尚不确定,初步的研究认为PET/MR应用于淋巴瘤的分期是可行的.笔者就多模态显像PET/CT、PET/MR在淋巴瘤中的研究现状及进展进行综述.
更多Medical imaging plays an important role in the clinical staging,restaging,and therapy assessment of tumors and may also serve as prognostic biomarker.Multimodal hybrid imaging technologies,such as PET/CT and recently PET/MR,have been rapidly developed in recent years.PET/CT is often recommended for the initial staging of FDG-avid lymphomas and therapy monitoring.The role of FDG PET/CT for interim therapy evaluation must be determined.Some feasibility studies indicated that using PET/MR for initial lymphoma staging is feasible.FDG PET/MR seemed to offer a comparable diagnostic performance compared with PET/CT.In this article,the research status and progress concerning multimodal hybrid imaging technologies,such as PET/CT and PET/MR,in malignant lymphoma are reviewed.
More- 浏览:131
- 被引:5
- 下载:114
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文